Posts Archive

First Posted 2021-10-25 Trial status Active, not recruiting Sponsor Hoffmann-La Roche Abstract Presentation Meeting Abstract: 2025 ASCO Annual Meeting I May 28, 2025 Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial. Click here for details Peer-reviewed journal publication Efficacy and safety of first-line maintenance t

First Posted 2020-10-19 Trial status Active, not recruiting Sponsor AstraZeneca Abstract Presentation Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC). Meeting Abstract: 2025 ASCO Annual Meeting II Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary June 04, 2025 Click here for det

First Posted 2020-10-19 Trial status Active, not recruiting Sponsor AstraZeneca Abstract Presentation Meeting Abstract: 2025 ASCO Annual Meeting II Free access Breast Cancer—Metastatic June 04, 2025 Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast0

First Posted 2019-04-23 Trial status Active, not recruiting Sponsor Merck Sharp & Dohme LLC Abstract Presentation Phase 3 KEYNOTE-905/EV-303: Perioperative pembrolizumab (pembro) or pembro + enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC). 2023 ASCO Genitourinary Cancers Symposium Click here for details Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin

First Posted 2018-07-03 Trial status Active, not recruiting Sponsor Groupe Oncologie Radiotherapie Tete et Cou Abstract Presentation NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse. Meeting Abstract: 2025 ASCO Annual Meeting II Head and Neck Cancer - June 04, 2025 Click here for details Press Release GORTEC Announces New Trial Suc

First Posted 2021-11-03 Trial status Active, not recruiting Sponsor AstraZeneca Abstract Presentation ESMO 2023 (Annals of Oncology) abstract (LBA11) LBA11 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial October 2023 Click here for details AACR 2024 (Cancer Research) abstract (GS02-01) Ab

First Posted 2021-11-24 Trial status Active, not recruiting Sponsor Seagen, a wholly owned subsidiary of Pfizer Abstract Presentation Her2climb-05: a randomized, double-blind, phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as maintenance therapy for her2+ metastatic breast cancer December 10, 2025 Click here for details Peer-reviewed journal publication HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Tr

First Posted 2022-11-21 Trial status Recruiting Sponsor Gilead Sciences Abstract Presentation Peer-reviewed journal publication Press Release FDA NCCN NCT05633654: Phase 3: (ASCENT-05/​AFT-65 OptimICE-RD/​GBG 119/​NSABP B-63) Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With TNBC (Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Hav

First Posted 2019-03-14 Trial status Active, not recruiting Sponsor AstraZeneca Abstract Presentation A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. 2022 ASCO Gastrointestinal Cancers Symposium Click here for details Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcita

First Posted 2017-01-30 Trial status Completed Sponsor Merck Sharp & Dohme LLC Abstract Presentation 2019 San Antonio Breast Cancer Symposium. Abstract GS3-03. Presented December 12, 2019. Schmid P, Park YH, Ferreira M, et al: KEYNOTE-522: Phase 3 study of neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy, followed by adjuvant pembrolizumab versus placebo for early triple-negative breast cancer: Pathologic complete response in key subgroups and by treatm